Drug Shortage Report for EMGALITY
Report ID | 173230 |
Drug Identification Number | 02505134 |
Brand name | EMGALITY |
Common or Proper name | galcanezumab injection |
Company Name | ELI LILLY CANADA INC |
Market Status | MARKETED |
Active Ingredient(s) | GALCANEZUMAB |
Strength(s) | 100MG |
Dosage form(s) | SOLUTION |
Route of administration | SUBCUTANEOUS |
Packaging size | Carton package containing three 100 mg/mL prefilled syringes |
ATC code | N02CD |
ATC description | |
Reason for shortage | Disruption of the manufacture of the drug. |
Anticipated start date | |
Actual start date | 2022-10-27 |
Estimated end date | 2023-01-16 |
Actual end date | 2023-01-16 |
Shortage status | Resolved |
Updated date | 2023-01-17 |
Company comments | For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays). |
Health Canada comments | |
Tier 3 Status | No |
Contact Address | EXCHANGE TOWER, 130 KING STREET WEST TORONTO, ONTARIO CANADA M5X 1B1 |
Company contact information | Lilly Canada’s Customer Response Centre 1-888-545-5972. |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
Version Number | Date Updated | Language | |
---|---|---|---|
v1 | 2022-11-01 | English | Compare |
v2 | 2022-11-01 | French | Compare |
v3 | 2023-01-16 | English | Compare |
v4 | 2023-01-16 | French | Compare |
v5 | 2023-01-17 | English | Compare |
Showing 1 to 5 of 5